These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33348190)

  • 1. Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population.
    Guo JD; Hlavacek P; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
    Thromb Res; 2021 Feb; 198():163-170. PubMed ID: 33348190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
    Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
    Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
    Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status.
    Cohen AT; Sah J; Dhamane AD; Lee T; Rosenblatt L; Hlavacek P; Emir B; Keshishian A; Yuce H; Luo X
    Adv Ther; 2021 Nov; 38(11):5519-5533. PubMed ID: 34570310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses.
    Weycker D; Wygant GD; Guo JD; Lee T; Luo X; Rosenblatt L; Mardekian J; Atwood M; Hanau A; Cohen AT
    Blood Adv; 2020 Jan; 4(2):432-439. PubMed ID: 31990332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
    Weycker D; Li X; Wygant GD; Lee T; Hamilton M; Luo X; Vo L; Mardekian J; Pan X; Burns L; Atwood M; Hanau A; Cohen AT
    Thromb Haemost; 2018 Nov; 118(11):1951-1961. PubMed ID: 30357780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences.
    Cohen AT; Sah J; Dhamane AD; Hines DM; Lee T; Rosenblatt L; Emir B; Keshishian A; Yuce H; Luo X
    Adv Ther; 2023 Apr; 40(4):1705-1735. PubMed ID: 36811795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
    Dawwas GK; Smith SM; Dietrich E; Lo-Ciganic WH; Park H
    Am J Health Syst Pharm; 2020 Jan; 77(3):188-195. PubMed ID: 31974557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
    Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
    JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
    Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X
    Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism.
    Park H; Kang HR; Huang PL; Lo-Ciganic WH; DeRemer CE; Wilson D; Dietrich EA
    Clin Transl Sci; 2023 Jan; 16(1):128-139. PubMed ID: 36200137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease.
    Cohen AT; Sah J; Dhamane AD; Lee T; Rosenblatt L; Hlavacek P; Emir B; Delinger R; Yuce H; Luo X
    Thromb Haemost; 2022 Jun; 122(6):926-938. PubMed ID: 34963185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apixaban: A Review in Venous Thromboembolism.
    Greig SL; Garnock-Jones KP
    Drugs; 2016 Oct; 76(15):1493-1504. PubMed ID: 27653758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial.
    Bleker SM; Cohen AT; Büller HR; Agnelli G; Gallus AS; Raskob GE; Weitz JI; Curto M; Sisson M; Middeldorp S
    Thromb Haemost; 2016 Nov; 116(6):1159-1164. PubMed ID: 27583312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding.
    Cohen AT; Sah J; Dhamane AD; Lee T; Rosenblatt L; Hlavacek P; Emir B; Keshishian A; Yuce H; Luo X
    PLoS One; 2022; 17(9):e0274969. PubMed ID: 36149864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
    Brekelmans MP; Scheres LJ; Bleker SM; Hutten BA; Timmermans A; Büller HR; Middeldorp S
    Thromb Haemost; 2017 Apr; 117(4):809-815. PubMed ID: 28180233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity.
    Crouch A; Ng TH; Kelley D; Knight T; Edwin S; ; Giuliano C
    Pharmacotherapy; 2022 Feb; 42(2):119-133. PubMed ID: 34904263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY.
    Cohen AT; Pan S; Byon W; Ilyas BS; Taylor T; Lee TC
    Adv Ther; 2021 Jun; 38(6):3003-3018. PubMed ID: 33890242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: A national cohort study.
    Ellenbogen MI; Ardeshirrouhanifard S; Segal JB; Streiff MB; Deitelzweig SB; Brotman DJ
    J Hosp Med; 2022 Oct; 17(10):809-818. PubMed ID: 35929542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
    Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
    J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.